At least five biotechs and pharmas reported earnings last week. Actelion Ltd. (SIX:ATLN) added more than $230 million to its market value after reporting 1Q13 revenues and EPS that beat the Street's estimates. "It is possible that some of the profit growth we forecasted for 2014 could be brought forward into this year," CFO Andrew Oakley said on the company's earnings call. Actelion has said it expects to maintain core earnings in local currencies at 2012 levels, with single-digit core earnings growth in 2014 and double-digit growth by 2015.

Baxter International Inc. (NYSE:BAX) fell 4%, or $1.5 billion in market value, after missing the consensus revenue estimate. Mcap in $M